Skip to main content
Dr. Lal Pathlabs Limited logo

Dr. Lal Pathlabs Limited — Investor Relations & Filings

Ticker · LALPATHLAB ISIN · INE600L01024 LEI · 984500E8E9CY102B9718 BSE.NS Human health and social work activities
Open in API
Filings indexed 1,098 across all filing types
Latest filing 2026-01-23 Regulatory Filings
Country IN India
Listing BSE.NS LALPATHLAB

About Dr. Lal Pathlabs Limited

https://www.lalpathlabs.com/

Dr. Lal Pathlabs Limited is a provider of diagnostic and related healthcare tests and services. The company offers a comprehensive range of clinical laboratory tests and profiles used for prediction, early detection, diagnostic screening, confirmation, and monitoring of diseases. Its service portfolio encompasses pathology, including biochemistry, hematology, clinical pathology, histopathology, and molecular diagnostics, as well as radiology services such as X-ray, ultrasound, and CT scans. The organization operates an extensive network of laboratories, patient service centers, and pick-up points, utilizing advanced automated systems and standardized processes. Key offerings include specialized wellness packages and home sample collection. The company maintains high quality standards through international and national accreditations, serving a diverse patient base and healthcare providers with a focus on accuracy and timely reporting.

Recent filings

Filing Released Lang Actions
Board Meeting — Board Meeting Intimation
Regulatory Filings
2026-01-23 English
Board Meeting — Dividend
Regulatory Filings Classification · 95% confidence The document is a short notice from the company to stock exchanges regarding an upcoming Board Meeting where the Board will consider and approve the unaudited financial results for the quarter and nine months ended December 31, 2025, and also consider the declaration of a 3rd interim dividend for the financial year 2025-26. The document does not contain the financial results themselves, only an announcement of the meeting and the agenda items. The length is only 1425 characters, which is quite short and consistent with an announcement rather than a full report. Therefore, this is an announcement related to dividend consideration and financial results approval, but not the actual financial report or dividend declaration. Given the content and length, the best fitting category is Notice of Dividend Amount (DIV) since it specifically mentions consideration of an interim dividend, although the dividend is not declared yet. However, since it is only an intimation of consideration and not the actual declaration, it is more appropriate to classify it as Regulatory Filings (RNS), which is the fallback for miscellaneous regulatory announcements that do not fit other categories. The document is not a full financial report, not a dividend declaration, and not a proxy or voting result. Hence, classification is Regulatory Filings (RNS) with high confidence.
2026-01-23 English
Analysts/Institutional Investor Meet/Con. Call Updates
Call Transcript Classification · 95% confidence The document is an invitation and intimation for an earnings conference call scheduled for January 30, 2026, to discuss Q3 & 9M FY26 financial results. It does not contain actual financial data or detailed financial statements but rather announces the upcoming call where such results will be discussed. The document is about notifying the market and investors about the conference call, not the earnings release itself or the transcript. Therefore, it fits the category of a Call Transcript (CT) invitation or announcement. However, since it is only an invitation and not the transcript, the best fitting category is Call Transcript (CT) as it relates directly to the earnings call content. Confidence is high due to clear mention of earnings call invitation and no financial data included.
2026-01-08 English
Certificate under SEBI (Depositories and Participants) Regulations, 2018
Regulatory Filings Classification · 95% confidence The document is a letter addressed to stock exchanges regarding compliance under Regulation 74(5) of SEBI (Depositories and Participants) Regulations, 2018, for the quarter ended December 31, 2025. It includes a certificate from the Registrar & Share Transfer Agent confirming compliance. The document is short (1113 characters) and serves as a regulatory compliance notification rather than a financial report or detailed filing. It does not contain financial statements or detailed analysis, nor does it announce voting results, management changes, or capital changes. It is primarily a regulatory compliance certificate submission. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements and compliance documents.
2026-01-07 English
Press Release
Capital/Financing Update Classification · 90% confidence The document is a press release announcing the launch of a new wellness centre by Dr. Lal PathLabs. It is addressed to stock exchanges under SEBI Listing Regulations and is titled as a "Press Release." There is no financial data, no report attached or referenced as being published, and no regulatory filing or certification. The content focuses on a business update about a new product/service launch rather than financial results, management changes, or regulatory compliance filings. Therefore, it fits best under Capital/Financing Update (CAP) as it relates to a significant business initiative that could impact the company's market position and investor interest.
2026-01-06 English
Board Meeting — Board Meeting Intimation
Regulatory Filings
2025-12-29 English

Browse filings by year

12 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.